United Therapeutics Announces Ralinepag Royalty Buydown
The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag.
Related stories
LiveOne Extinguishes $8.5 Million in JGB Debt
LiveOne says it reduced its JGB debt balance from $17.5 million to $9 million.
M impact | EQUITY | Nov 04, 2026, 02:04 PM UTC
Netskope Sets December 2 Date for Fiscal Q3 2027 Results
Netskope says it will report fiscal third-quarter 2027 financial results on December 2, 2026.
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Hackett Group Reports Q3 2026 Results, Issues Q4 Guidance
The Hackett Group reported Q3 revenue of $69.8 million, GAAP diluted EPS of $0.14 and adjusted diluted EPS of $0.39, at the high end of guidance. Operating income rose to $7.5 mill
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Ardelyx Reports Third-Quarter Revenue of $125.5 Million, Up 19%
Ardelyx reported total product revenue of $125.5 million for the quarter ended September 30, 2026, up 19% from the same period in 2025. The company reiterated full-year 2026 revenu
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
InnovAge Reports Fiscal Q1 2027 Revenue of $264.8 Million
Revenue rose 12.1% year over year and income before taxes increased 153.1% to $20.0 million. Diluted EPS was $0.14 versus analyst expectations of $0.09. Fiscal 2027 revenue guidanc
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC
Shoals Technologies Reports Q3 Revenue of $195.3 Million, Raises 2026 Outlook
Revenue rose 43.8% year over year to $195.3 million, and adjusted EBITDA reached $39.8 million, above the company’s expected range. Shoals guided to fiscal 2026 revenue of $665 mil
M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC